Posted on

cv sciences cbd

CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based dietary supplements and CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics. The Company’s PlusCBD™ products are sold at more than 7,700 retail locations throughout the U.S. and it is the top-selling brand of hemp-derived CBD in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s products are processed, produced, and tested throughout the manufacturing process to confirm strict compliance with company standards and specifications. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PlusCBD™ was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California. Additional information is available from or by visiting

SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the third quarter ended September 30, 2021, before the stock market opens on Monday, November 15, 2021. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) that same day.

The webcast of the conference call will be available on the Investor Relations section of the Company’s website at or directly here. The webcast will be archived for approximately 30 days. Investors interested in participating in the live call can also dial (877) 407-0784 from the U.S. or international callers can dial (201) 689-8560. Please dial the conference telephone number 15 minutes prior to the start time due to increased demand for conference calls.

About CV Sciences, Inc.

November 08, 2021 08:00 ET | Source: CV Sciences, Inc. CV Sciences, Inc.

A telephone replay will be available approximately two hours after the call concludes and will be available through Monday, November 22, 2021, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 13724286.

San Diego, California, UNITED STATES

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risk and uncertainties.

SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, applauds the California Legislature of its passage of AB 45, which yesterday was signed into law by Governor Gavin Newson. This new law will explicitly permit the retail sale of products containing hemp-derived extracts and cannabinoids, such as CBD.

October 07, 2021 13:01 ET | Source: CV Sciences, Inc. CV Sciences, Inc.

Additional information is available from or by visiting

San Diego, California, UNITED STATES

“As a California-based company, we are very pleased with the enactment of AB 45, which we believe will lead to significant retail expansion of CV Sciences’ PlusCBD™ products in our home state, while also serving as a model for responsible CBD legalization for other states,” said Joseph Dowling, Chief Executive Officer of CV Sciences. “AB 45 will provide Californians with access to the health and wellness benefits of our safe and effective hemp-derived CBD. We look forward to working with our retail partners to rapidly expand our distribution footprint in California.”

Cv sciences cbd

Our CBD Softgels are beautiful in their simplicity.


Always from EU certified hemp seeds. Non-GMO. Vegetarian. Gluten-Free. Always third party tested. Try our CBD Oil softgels today to see why we’re America’s favorite hemp company.


Just 4 ingredients: CBD-rich hemp extract made of modified corn starch, extra virgin olive oil as the carrier, carrageenan, sorbitol, and in a vegetarian softgel capsule. It’s an ideal method for sensitive palates or sensitive stomachs.